Efficacy, Quality of Life Improvement, and Longevity of Risankizumab in Individuals with Moderate-to-Severe Psoriasis: Insights from the PRIMMA Study's Real-World Data - Quiz - MDSpire

Efficacy, Quality of Life Improvement, and Longevity of Risankizumab in Individuals with Moderate-to-Severe Psoriasis: Insights from the PRIMMA Study's Real-World Data

  • By

  • Igor Snast

  • Yuliya Valdman-Grinshpoun

  • Naji Bathish

  • Hagit Matz

  • Yuri Shclar

  • Sari Murad

  • Tali Czarnowicki

  • Eran Shavit

  • Liuqing Yang

  • Sandra Goss

  • Inbal Piller Maor

  • Assaf Halperin

  • Shiran Naftalberg Blonder

  • Raanan Cohen

  • Alex Bleterman

  • Moran Barak

  • Lev Pavlovsky

  • March 31, 2026

  • 0 min

Share

Original Source(s)

Efficacy, Quality of Life Improvement, and Longevity of Risankizumab in Individuals with Moderate-to-Severe Psoriasis: Insights from the PRIMMA Study's Real-World Data

  • by Igor Snast, Yuliya Valdman-Grinshpoun, Naji Bathish, Hagit Matz, Yuri Shclar, Sari Murad, Tali Czarnowicki, Eran Shavit, Liuqing Yang, Sandra Goss, Inbal Piller Maor, Assaf Halperin, Shiran Naftalberg Blonder, Raanan Cohen, Alex Bleterman, Moran Barak, Lev Pavlovsky

  • March 31, 2026

Related Content

Understanding the Perspectives and Experiences of Canadian Psoriasis Patients with Diverse Skin Tones

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial

The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa—A Narrative Review